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Over the past 20 years, the immune effector mechanisms involved in the control of Trypanosoma cruzi, as well as the receptors
participating in parasite recognition by cells of the innate immune system, have been largely described. However, the main
questions on the physiopathology of Chagas disease remain unanswered: “Why does the host immune system fail to provide sterile
immunity?” and “Why do only a proportion of infected individuals develop chronic pathology?” In this review, we describe the
mechanisms proposed to explain the inability of the immune system to eradicate the parasite and the elements that allow the
development of chronic heart disease. Moreover, we discuss the possibility that the inability of infected cardiomyocytes to sense
intracellular T. cruzi contributes to parasite persistence in the heart and the development of chronic pathology.
1. A Brief Overview of Chagas Disease
Chagas disease is caused by Trypanosoma cruzi and rep-
resents an important health problem in Latin America,
with approximately 8 million chronically infected people [1].
Recently, as a consequence of humanmigrations, Chagas dis-
ease has become a potential public health issue in developed
countries, and significant increases in confirmed cases have
been reported in the USA, Canada, Europe, Japan, and Aus-
tralia [2]. The invasion of the human host frequently occurs
by the passage through damaged skin or intact mucosa of
metacyclic trypomastigotes releasedwith the feces of infected
triatomines after their blood meal. Alternatively, infection
through other routes, such as oral, congenital, and blood
transfusion/organ transplantation, also occurs. Because it is
an obligate intracellular parasite, T. cruzi can be found in
the vertebrate host as amastigotes, the intracellular replicative
form, and as extracellular trypomastigotes circulating freely
in the blood and tissues. The infection has a self-limiting
acute phase, with patent (or subpatent) parasitemia, which
goes unnoticed inmany infected individuals. At this stage, the
parasites actively replicate in many different cell types, such
as macrophages; smooth, striated, and cardiac muscle cells;
adipocytes; and cells of the central nervous system [3].
While a small proportion of patients succumbs to the
acute phase of the disease, the development of the adaptive
immune response typically provides control of the T. cruzi
infection, albeit nonsterile control. Failing to completely
eradicate the parasite, individuals remain infected for life
and establish a dynamic equilibrium with the parasite that
results in different clinical outcomes. Thus, while many
chronically infected individuals remain in the asymptomatic
indeterminate phase, a significant proportion (30–35%) of
patients develop the cardiac or digestive manifestations of
chronic disease: cardiomyopathy that may lead to congestive
heart failure, arrhythmia and, eventually, patient death, and
esophageal or colonic megasyndromes.These are irreversible
pathological changes that occur despite parasite scarcity.
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Recapitulating human chagasic myocarditis, mice surviving
long-term infection by certain stocks of T. cruzi develop
chronic myocardial lesions [4, 5].
2. The Host Immune Response against T. cruzi
The immune system is well equipped to detect and control
T. cruzi parasites through the combined effect of diverse
branches of the immune response. CD4+ and CD8+ T cells,
as well as B cells, contribute to control the parasite through
cytokine secretion, cellular cytotoxicity, and specific antibody
production [6–8]. From the end of the acute phase and
throughout chronic infection,T. cruzi-specific IgG antibodies
actively participate in the removal of extracellular parasites
released from ruptured tissue nests, an effect that presumably
occurs by promoting parasite phagocytosis by macrophages
and neutrophils. In addition, specific IgG antibodies mediate
the removal of blood trypomastigotes, a clearance process in
which complement and mononuclear phagocytes from the
liver, spleen, and lungs appear to be involved [9–11]. The
IFN-𝛾 produced by activated CD4+ and CD8+ T cells, NK
cells, and CD4−CD8−𝛾𝛿 T cells plays a crucial role in parasite
elimination [12, 13]. IFN-𝛾 potentiates the effector activity of
macrophages by inducing the transcription of the inducible
nitric oxide synthase (iNOS) gene, notably increasing the
production of nitric oxide, which has a potent effect on
T. cruzi killing [14, 15]. In addition, IFN-𝛾 promotes the
immunoglobulin switch to IgG subclasses with high opsoniz-
ing and complement-activating potential. Lastly, cytotoxic
CD8+ T cells also contribute to T. cruzi control through the
recognition and destruction of cells that harbor intracellular
forms of the parasite [16].
3. Limitations to the Innate and Acquired
Immune Responses That Contribute to
Parasite Persistence
One of the most intriguing questions of human and experi-
mental T. cruzi infection is why the immune system fails to
totally eradicate the parasite. At first glance, the inability of
the infected host to attain sterility suggests that the immune
effector activity directed against the parasite is insufficient
or inappropriate due to defective activation of the specific
immune response or excessive regulation of this response.
In this context, we outline in this section the different
escape mechanisms employed by T. cruzi parasites and dis-
cuss the hypothesis generated to explain an immune system
failure. At the beginning of the infection (before development
of the parasite-specific response), T. cruzi trypomastigotes
escape lysis by the complement system, an evasion strategy
that results from the presence of complement-regulatory
molecules on the parasite surface [17]. In addition, internal-
ized parasites of diverse T. cruzi strains escape the phagocytic
vacuole of unprimed resident macrophages [18], a strategy
that relies on a variety of molecules with antioxidant prop-
erties [19, 20]. Nevertheless, as infection progresses, these
two evasion strategies are largely circumvented by the devel-
opment of the specific humoral response and the induction
of macrophage activation by IFN-𝛾 and other cytokines.
Because T. cruzi strains display different levels of antioxidant
activity that directly correlate with strain virulence [21], it
remains unclear whether IFN-𝛾 confers effectivemacrophage
protection against any T. cruzi parasite or results in different
degrees of intracellular parasite destruction for different
isolates.
Pattern recognition receptors (PRRs), such as toll-like
receptors (TLRs) 2, 4, 7, and 9, nucleotide-binding oligomer-
ization domain-like receptor (NOD) 1 and NATCH, LRR,
and PyD domains-containing protein 3 (NLRP3) have been
shown to participate inT. cruzidetection bymacrophages and
dendritic cells [22–27]. However, a deficient innate immune
response due to poor PRR signaling by pathogen-associated
molecular patterns (PAMPs) has been proposed as a mecha-
nism involved in parasite escape.This hypothesis is supported
by data showing that, compared with mice infected by wild-
type T. cruzi parasites, mice infected with transgenic T. cruzi
expressing Salmonella typhimurium flagellin (fliC) display
an increased innate response mediated by macrophages and
dendritic cells and notably enhanced adaptive immunity [28].
More importantly, in the chronic phase, mice infected with
fliC-transgenicT. cruzidisplay notably reduced parasite levels
in relation to those infected with wild-type parasites.
Parasite persistence has also been attributed to the rel-
atively slow development of T. cruzi-specific CD8+ T effec-
tor cells [29], a phenomenon explained by diverse factors,
including the postulated poor PAMP activity of T. cruzi [28]
and the induction of a strong Fas expression on T. cruzi-
specific CD8+ T cells [30]. Another possible reason for the
failure to acquire sterile immunity is the clonal dominance
of the lymphocyte response to T. cruzi infection. This is
illustrated by the observation that the CD8+ T cell response to
the abundantly expressed T. cruzi antigen amastigote surface
protein-2 (ASP2) is restricted to a small number of clones [31].
Narrowing the scope of parasite peptides that are recognized
by CD8+ T cells may impair complete parasite eradication
during chronic infection and the control of reinfection, which
frequently occurs in endemic areas.
An alternative mechanism that restricts the efficiency
of adaptive immunity in eliminating T. cruzi parasites is
the negative regulation of effector lymphocytes because of
persistent stimulation. The senescence of CD4+ T cells [32]
and exhaustion of CD8+ T cells that infiltrate the heart
or striated muscle of chronically infected hosts have been
observed during chronic infection [33, 34]. In this context, it
was suggested that the parasite can survive inside myocardial
or striatedmuscle cells because followingmigration to the tis-
sues CD8+ T cells lose their cytotoxic and IFN-𝛾-producing
capacities [35]. Also suggesting the negative regulation of the
effector response, Albareda and cols [36] reported that CD4+
T cells from patients with long-term chronic infection are
primarily monofunctional, whereas in children in the early
chronic stage of infection, multifunctional responses are also
observed. Last, the expression of PD-1 and PD-L1 regulatory
molecules has been shown to downmodulate the effector
activity of CD4+ and CD8+ T cells in T. cruzi-infected mice
[37]. While PD-L1-PD-1 regulatory interaction was observed
in the acute phase of infection, its roles in limiting parasite
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Figure 1: Expression of PD-L1 by infiltrating leukocytes in a chronically infected heart. C3H/HePAS mice were infected with 4 × 105 Sylvio
X10/4 trypomastigotes obtained from LLCMK2 cultures. At day 400 postinfection, mice were sacrificed, and the heart tissue was digested
with collagenase to isolate the infiltrating leukocytes. PD-L1 expression was analyzed by flow cytometry. Heart leukocytes from a pool of
age-matched noninfected mice were also included.
elimination and permitting the perpetuation of lesions in
the chronic phase remain to be determined. In this respect,
our data showing the intense expression of PD-L1 in the
heart-infiltrating leukocytes of mice chronically infected by
Sylvio X10/4 T. cruzi parasites suggest the involvement of this
regulatory circuit in parasite persistence (Figure 1).
The mechanisms of parasite escape discussed above
refer to limitations of the innate or acquired protective
immune response to T. cruzi that appear to operate in all
infected individuals. However, in addition to these gen-
eral elements, we must consider that individuals differ in
the intensity/effectiveness of their anti-T. cruzi humoral
and cellular responses, a consequence of polymorphisms
in genes associated with the immune response [38]; these
polymorphisms influence the intensity of the anti-T. cruzi
effector activity, yielding different levels of residual parasites
and undesired tissue lesions in chronically infected human
patients. In addition, these polymorphisms influence the
residual parasite distribution in different tissues/organs, an
element closely connected to the development of the different
forms of the disease.
The isogenic strains of mice also differ in the immune
response to T. cruzi. These differences are often critical for
acute phase survival [39] and most likely determine the par-
asite load in the chronic phase. However, not a single mouse
strain has been reported to promote the complete elimination
of the parasite. Therefore, regardless of the mouse/parasite
strain combination, the inevitable outcome of murine infec-
tion by T. cruzi appears to be parasite persistence, a result
analogous to that observed in human patients.
4. Only a Proportion of T. cruzi-Infected
Individuals Show Chronic Pathologies
A significant proportion of chronically infected individuals
develop the cardiac and digestive forms of the disease,
but the largest fraction present the indeterminate form.
Importantly, although many indeterminate patients remain
asymptomatic for the rest of their lives, it is estimated that,
each year, 2.5% of infected individuals evolve from the
indeterminate to the clinical forms [40]. Chronic chagasic
cardiomyopathy (CCC) represents the main cause of death
in T. cruzi-infected patients. Moreover, this clinical form
represents an important social burden in terms of lost labor
hours and hospital costs. The situation of CCC patients is
worrisome because the specific anti-T. cruzi drugs, currently
limited to benznidazol and nifurtimox, show limited efficacy
in chronically infected patients.
Because of parasite scarcity in the inflamed heart, CCC
was long considered an autoimmune disease directed against
self-epitopes showing cross-reactivity with parasite antigens
[41]. According to this view, lesions were thought to occur as
a result of T cell reactivity against myosin and other heart-
derived proteins [42] as well as humoral reactivity to the
beta-1-adrenergic and M2 cholinergic receptors, leading to
autonomic nervous system imbalance [43]. However, in the
last 20 years, cumulative evidence has promoted a change
in our understanding of this process. First, immunohis-
tochemistry data showed that, in patients with CCC, the
level of T. cruzi antigen correlated with the intensity of the
inflammatory infiltrate [44]. Furthermore, T. cruziDNA was
found in the heart of diseased CCC patients but not in
the heart of patients with the indeterminate form [45]. In
contrast, patients with megaesophagus, one of the digestive
forms of the disease, displayed positive PCR for T. cruzi
kinetoplast DNA in the esophagus [46]. Confirming the
human studies, in mice chronically infected by T. cruzi, we
previously observed that live parasites were only detected in
the heart of mice with cardiomyopathy, although these mice
displayed subpatent blood parasite levels similar to those in
mice with no heart pathology [47]. Based on the data from
these and other important reports, at present, it is largely
4 Mediators of Inflammation
(a) (b)
Figure 2: Parasite persistence is not the necessary outcome of heart infection by T. cruzi parasites. C57BL/6 mice were infected with 103 T.
cruzi blood trypomastigotes of the Y strain. At days 18 (a) and 180 (b) postinfection, mice were sacrificed, and the heart tissue was formalin-
fixed, included in paraffin, and stained with hematoxylin/eosin. Arrow in the figure shows an amastigote nest, which ismagnified at the insert.
Bars in figures correspond to 200𝜇m and to 100𝜇m at the insert.
agreed that the inflammatory infiltrate in CCC is caused
by a response directed toward locally persisting parasites
[48]. Still, because Chagas disease is a highly heterogeneous
process influenced by host genetics, we cannot discard that
the immune response in the heart of CCC patients could
include, besides leukocyte reactivity towards locally persist-
ing parasites, different degrees of autoreactivity. Furthermore,
it is possible that a proportion of CCC patients shows cardiac
pathology in the absence of locally persisting infection.
This last possibility is illustrated by a recent report using
bioluminescence imaging, inwhichmice chronically infected
with luciferase expressingT. cruzi parasites displaymild heart
inflammation in the absence of local parasitism [49]. Further
studies on the contribution of autoimmunity are required for
a full comprehension of CCC physiopathology.These studies
may eventually reveal alternative therapeutic approaches to
attenuate heart tissue inflammation in chagasic patients.
Nonetheless, because most data suggest the association
of chronic cardiac pathology with local parasite persistence,
CCC is presently understood as an expression of the host’s
incapacity to totally eliminate the heart parasitism, a particu-
larity of the host’s failure to eradicate T. cruzi from the organ-
ism.This leads us to question why heart parasitism occurs in
only a fraction of T. cruzi chronically infected individuals.
5. Where Does T. cruzi Persist in
the Chronically Infected Host?
The tissue distribution of T. cruzi parasites varies among
chronically infected individuals. As indicated above, patients
with cardiomyopathy andmegaesophagus harbor parasites in
the heart and esophagus, respectively. However, are there in
these patients, aswell as in thosewith the indeterminate form,
other locations where the parasite is relatively safe from com-
plete elimination by the immune system? A priori, because
parasite persistence is the rule, it is reasonable to hypothesize
that immune-privileged T. cruzi reservoirs must exist in all
chronically infected hosts. One of these parasite niches could
be the central adrenal vein, which, in autopsy studies of
patients with chronic Chagas disease, has been found to
frequently harbor amastigote nests; further, the presence of
these nests shows a close correlation with heart pathology
parameters such as the intensity of leukocyte infiltration and
myocardial fibrosis [50]. Additionally, both brown and white
adipose tissues, as well as the colon and stomach, have been
described as locations where T. cruzi parasites chronically
persist [49, 51, 52]. Moreover, because of parasite persistence
in the cardiac tissue of CCC patients, the heart could be one
of these niches for a fraction of the infected population.
Another issue is whether parasite dissemination through
the blood or by spreading from neighboring tissues occurs in
the chronic host. Are the T. cruzi found in the hearts of CCC
patients the consequence of chronic phase dispersion from
other tissues or do they result from the perpetuation of heart
colonization during the acute phase? This is an important
question because chronic phase reinvasion could readdress
the problem of heart parasite persistence outside the cardiac
tissue.
On the other hand, it is important to note the observation
made by different research groups that mice from certain
strains can eliminate T. cruzi from the heart. This occurs
in C57BL/6 mice infected with a sublethal dose of Y strain
parasites; thesemice exhibit strong leukocyte infiltrationwith
the presence of amastigote nests in the heart in the late acute
phase but no signs of infection or pathology in this organ
in the chronic phase (Figure 2). This observation indicates
that parasite persistence is not the necessary outcome of heart
infection. Moreover, these results open the possibility that
the indeterminate group of human patients might include
patients in whom the cardiac infection was resolved in addi-
tion to individuals in whom the heart was never colonized by
the parasite.
6. Elements Involved in Parasite
Persistence in the Heart or Other
Tissues: Parasite Tropism
T. cruzi displays a broad heterogeneity, being currently
classified in six different groups (I-VI) [53] that show discrete
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correlations with the sylvatic or peridomestic forms of trans-
mission as well as with the occurrence (or lack thereof) of
different chronic pathologies. Mixed infections by multiple
T. cruzi isolates are frequently observed in chronic chagasic
patients.
Parasite tropism was originally defined as the preferential
invasion of a cell type by aT. cruzi clone/isolate. Nevertheless,
because the infected host exhibits considerable variability
in its tissue responses to the parasite, tropism has to be
redefined as the outcome of the interaction of a defined
T. cruzi clone/isolate in a particular individual, a process
largely dependent on the parasite and host genetics. The
importance of the host in the development of chronic heart
pathology by a single T. cruzi parasite is clearly illustrated
in the murine model of infection by parasites of the T. cruzi
clone Sylvio X10/4, which results in chronic cardiomyopathy
in C3H/HePAS mice but not in C57BL/6 or A/J mice [47].
Therefore, while (at least for mice and men) the lack
of a spontaneous cure and, consequently, the persistence of
the parasite are general problems associated with T. cruzi
infection, independent of parasite and host diversity, the
development of chronic heart disease appears to be limited
to particular host-parasite combinations.
7. Is Parasite Persistence Merely the Result of
a Deficit in the Local Immune Response?
Different research groups have analyzed the heart-infiltrating
leukocytes of CCC patients and mice with chronic car-
diomyopathy [54–58]. These studies have yielded valuable
data regarding the distribution of leukocyte populations,
surface marker expression, and the production of cytokines,
chemokines, and other mediators. Nonetheless, the gathered
information did not help to determine whether a local
immune deficit exists because the characteristics of an effec-
tive local immune response are undefined. This is because in
those chronic settings in which an effective response could
eventually occur, such as in chronically infected mice with
no cardiac pathology or in patients with the indeterminate
form, there are by definition no heart infiltrates to dissect.
Therefore, if there is a defect in the local immune response
in the heart of CCC patients, it has yet to be found.
Immune response analysis of the blood of patients with
the cardiac and indeterminate forms has been used as an
indirect means of searching for the presumed local immune
defect, aiming to reveal a special immune signature that
would explain why the parasite persists in the heart of CCC
patients. Remarkably, these studies have revealed that the
production of IFN-𝛾 and other proinflammatory cytokines is
higher in CCC patients than in indeterminate form patients
[59–61] and that asymptomatic patients exhibit augmented
TREG numbers and IL-10 levels [59, 62]. Because a proin-
flammatory response is considered the appropriate approach
to eliminate T. cruzi parasites, these results conflict with the
hypothesis that parasite evasion is the result of a deficient
immune response. Furthermore, while systemic studies do
not suggest a local deficit in the anti-T. cruzi immune
response of CCC patients, they do indicate that these patients
Figure 3: Lack of sensing of amastigote nests could contribute
to parasite perpetuation and pathology in the chronically infected
heart. Lack of sensing could occur independently of the origin
of cardiomyocyte-invading trypomastigotes, that is, from a local
ruptured nest or metastasis from a distant niche. The heart picture
shown corresponds to a C3H/HePAS mouse infected for more than
200 days with 106 Sylvio X10/4 trypomastigotes. The tissue section
was stained with hematoxylin-eosin. Bar corresponds to 100 𝜇m
(reproduced fromC. R. F.Marinho,Microbes and Infection [64] with
permission from Elsevier).
display an aggressive deregulated response that may explain
the presence of tissue damage in the affected heart [63].
What, then, is missing? How can we explain why patients
with greater proinflammatory responses to T. cruzi are those
with lower heart parasite control? An interesting possibility
is that T. cruzi persistence in the heart (and in other relatively
immunoprivileged locations) is not merely the consequence
of a defective local immune response but that it, to a large
extent, derives from the parasite’s ability to remain unnoticed
inside the structural cells, safe from the effector activity of
cytotoxic CD8+ T cells [64]. Illustrative evidence of this
possibility is shown in Figure 3, where an amastigote nest
can be observed amid myocardial fibers in a mouse infected
for more than 200 days, that is, in an animal with a high
level of anti-T. cruzi immune effector activity.While a notable
feature of this picture is the nest size, the most impressive
aspect is the absence of leukocytes surrounding it. This
suggests a deficiency in signaling for leukocyte recruitment,
a condition that allows the parasite to temporarily evade
the immune system. Anecdotally, the presence of heart
amastigote nests undetected by the inflammatory response
was described by Vianna [65] in 1911, one year after the
discovery of Chagas disease. From these observations, we can
postulate that, independently of the cardiomyocyte-invading
parasites originating from a local ruptured nest or a distant
niche, the failure to attain sterile immunity in the heart
may to a large extent result from an intrinsic or acquired
deficit of the cardiomyocytes in sensing the intracellular
parasite. Because leukocyte recruitment requires infected
cardiomyocytes to signal the presence of an infection through
the secretion of chemotactic molecules, we can speculate
that, in patients with chronic cardiac disease, this mechanism
is largely suppressed. Meanwhile, T. cruzi-infected neonatal
cardiomyocytes have been shown in vitro to transcribe the
genes for the chemokines MCP-1, RANTES, KC/GRO, MIP-
2, MIG, and IP-10 together with those for the cytokines
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TNF-𝛼 and IL-1𝛽 [66]. A way to reconcile these in vitro
and in vivo findings is that the failure of cardiomyocyte
signaling in vivo could be an adaptive trait that develops
during the course of infection in only certain parasite-host
combinations. The possibility that T. cruzi interferes with the
physiology of infected structural cells is supported by other
studies. In this manner, cruzipain, an enzyme abundantly
found in T. cruzi parasites, has been shown to interfere with
cardiomyocyte apoptosis through activation of the NF𝜅B
and PI3K/Akt and MEK1/ERK1/2 pathways in the host cell,
which lead to increased expression of antiapoptotic Bcl-
2 molecules and increased arginase expression [67]. It is
therefore conceivable that the crosstalk of the intracellular
parasite with the signaling pathways of these structural
cells might negatively impact the production of chemotactic
molecules.
A deficit in intracellular parasite sensing, although
important, is insufficient to guarantee T. cruzi evasion in the
chronically infected heart. This is the case given that, sooner
or later, an undetected amastigote nestwill spontaneously dis-
rupt, releasing extracellular parasites that, after detection by
antibodies, will cause complement and resident macrophages
to generate mediators for leukocyte recruitment. Thus, for
long-term parasite perpetuation to occur, it is predictable
that a small fraction of nest-released trypomastigotes will
reinvade relatively distant cardiomyocytes, where they may
remain unnoticed and out of the reach of cytotoxic CD8+ T
cells in the newly formed infiltrate.
As stated above, defective parasite sensing by cardiomy-
ocytes could be an adaptive process of the heart tissue that
develops with the length of infection.This process most likely
exhibits a great degree of variability, reflecting the genetics
of the host and the parasite. Moreover, its occurrence in the
cardiac tissue is not surprising because the heart is a vital
organ that must have special mechanisms designed to protect
its integrity.
8. Local Parasite Destruction
versus Immunopathology
Theoretically, if two hosts are unable to control tissue par-
asites, the one with a greater local inflammatory response
will pay a higher price by provoking greater damage of
the infected tissue [68]. Therefore, if defective local sensing
occurs in CCC patients, strong local immune responses
would clearly represent a detrimental factor in the induc-
tion of pathology, thus explaining the reported associa-
tions between high levels of cardiac dysfunction and geno-
types associated with high reactivity [69, 70]. Furthermore,
the inverse correlation observed in CCC patients between
the intensity of electrocardiogram abnormalities and IL-10
plasma levels [59] reinforces this view. That is, to respond
strongly when there is a gap in local T. cruzi control clearly
represents a deleterious manner of dealing with the parasite.
Entering into a persistent cycle of an intense local effector
response with no resolution is, to a certain extent, a form
of autoaggression, considering the high price paid by the
organism in terms of tissue damage. It is not, however,
an aggression specifically directed against self-antigens but
the unwanted price for unceasingly attempting to completely
eliminate a small number of parasites that persist in a
fraction of chronically infected individuals. Paradoxically, to
protect heart integrity, cardiomyocytes may allow parasite
persistence, which indirectly results in tissue damage every
time a nest breaks open and new leukocyte infiltrates are
formed.
A deficit in the interaction of T. cruzi parasites with
tissue structural cells could also be involved in parasite
persistence at locations other than the heart.This could occur
in any infected patient, independent of whether the infection
is cardiac, digestive, or indeterminate. In contrast to the
heart, however, in many of these locations, the bystander
tissue damage resulting from the persistent immune reaction
against parasites might not be sufficient to compromise the
function of the infected tissue.
Future Perspectives
While extensive research has deciphered the local and sys-
temic immune responses of chronically T. cruzi-infected
hosts in the last two decades, future studies will need to focus
on the in vivo interaction of parasites with structural cells,
in both the heart and other tissues. Although these studies
currently face great technical challenges, they will be of great
importance to improve our knowledge about Chagas disease
pathology.
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